Instruction 1(b).

Г

FORM 4

Check this box if no longer subject

to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
MB Number	3235-028						

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* RIGGS RORY B			2. Issuer Name and Ticker or Trading Symbol Intra-Cellular Therapies, Inc. [ITCI]				(Chec	ationship of Reportink all applicable)	0 ()			
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/31/2024					Director Officer (give title below)	10% C Other below	(specify	
C/O INTRA-CELLULAR THERAPIES, INC. 430 EAST 29TH STREET			C. 4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)				6. Indi Line) X	-)			
(Street) NEW YORK	NY	10016								Form filed by On Form filed by Mo Person	1 0	
,			Ri	Rule 10b5-1(c) Transaction Indication								
(City) (State) (Zip)				Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
Date		2. Transaction Date (Month/Day/Yea	Execution Date,		action (Instr.				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
				Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock 03/31/2		03/31/2024		A		260	Α	\$69.2	99,495	D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned												

(e.g., puts, calls, warrants, options, convertible securities) 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. 11. Nature 2. Transaction Code (Instr. Execution Date, if any (Month/Day/Year) Ownership Derivative Conversion Date Expiration Date (Month/Day/Year) Amount of Derivative derivative of Indirect Beneficial Security (Instr. 3) Security (Instr. 5) Form: Direct (D) or Exercise (Month/Day/Year) Derivative Securities Securities Securities Acquired (A) or Disposed Price of 8) Underlying Beneficially Ownership Owned Following Reported or Indirect (I) (Instr. 4) Derivative Derivative (Instr. 4) Security Security (Instr. 3 and 4) of (D) (Instr. 3, 4 Transaction(s) (Instr. 4) and 5) Amount or

> Date Exercisable

Explanation of Responses:

/s/ Lawrence J. Hineline, Attorney-in-fact

Numbe

of Shares

Title

Expiration Date

04/02/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code V

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(A)

(D)